Transgenomic Sales Dip 12 Percent; CEO 'Optimistic' on New Launches | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Wednesday that its revenues in the second quarter of 2009 were down 12 percent compared with the 2008 period, and it saw a profit swing to a loss.

The Omaha, Neb.-based genetic test provider said that it brought in revenues of $5.5 million for the three-month period ended June 30, compared with $6.2 million a year ago.

Transgenomic posted a loss of $730,000, or $.01 per share, compared to a net profit of $101,000, or $.00 per share, in the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.